What does this research mean for the field?

A pharmacist-led service utilizing DCES-credentialed pharmacists within an interprofessional care team significantly improves the initiation and use of SGLT2 inhibitors for patients with chronic kidney disease and heart failure in primary care settings. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to expand the use of SGLT2 inhibitors in patients with chronic kidney disease and heart failure through pharmacist-led services.

April 10, 2026

Implementation of a Pharmacist-Led Service to Expand SGLT2 Inhibitor Use Beyond Diabetes in the Primary Care Setting

Key Result

A pharmacist-led service significantly improved SGLT2 inhibitor use among primary care patients with chronic kidney disease and heart failure.

Key Points

The aim is to expand the use of SGLT2 inhibitors in patients with chronic kidney disease and heart failure through pharmacist-led services.
Implemented a pharmacist-led service in primary care settings
Utilized DCES-credentialed pharmacists
Focused on initiating SGLT2 inhibitor therapy for CKD and HF patients
Significant improvement in SGLT2 inhibitor use for CKD and HF patients
Demonstrated feasibility of pharmacists in interprofessional care teams

Structured PICO

Does a pharmacist-led service improve SGLT2 inhibitor use in patients with CKD and HF in the primary care setting?

Population

Patients with chronic kidney disease (CKD) and heart failure (HF) in the primary care setting

Intervention

Pharmacist-led service (DCES-credentialed pharmacists in an interprofessional care team) to initiate SGLT2 inhibitor therapy

Outcome

SGLT2 inhibitor use

A pharmacist-led service is feasible and significantly improves the initiation of SGLT2 inhibitors for patients with CKD and HF in primary care.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

This initiative resulted in a significant improvement in SGLT2 inhibitor use for patients with CKD and HF. The findings highlight the feasibility of using DCES-credentialed pharmacists in an interprofessional care team to initiate SGLT2 inhibitor therapy for patients with these conditions in the primary care setting.

Bookmark